GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Piotroski F-Score
中文

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 2008. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ono Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Ono Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

OPHLY' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Ono Pharmaceutical Co was 9. The lowest was 4. And the median was 6.


Ono Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Ono Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 6.00 7.00 8.00

Ono Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 7.00 7.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ono Pharmaceutical Co Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 127.686 + 225.088 + 288.633 + 250.393 = $892 Mil.
Cash Flow from Operations was 333.268 + -68.181 + 313.565 + 172.085 = $751 Mil.
Revenue was 809.244 + 849.021 + 938.124 + 911.166 = $3,508 Mil.
Gross Profit was 612.662 + 635.577 + 704.136 + 697.958 = $2,650 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(6156.026 + 6601.89 + 6167.867 + 6059.846 + 6193.33) / 5 = $6235.7918 Mil.
Total Assets at the begining of this year (Dec22) was $6,156 Mil.
Long-Term Debt & Capital Lease Obligation was $44 Mil.
Total Current Assets was $2,461 Mil.
Total Current Liabilities was $623 Mil.
Net Income was 134.081 + 220.04 + 229.348 + 246.948 = $830 Mil.

Revenue was 758.416 + 796.659 + 767.558 + 906.639 = $3,229 Mil.
Gross Profit was 565.487 + 595.58 + 580.699 + 683.72 = $2,425 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(6501.258 + 6233.928 + 5704.51 + 5618.257 + 6156.026) / 5 = $6042.7958 Mil.
Total Assets at the begining of last year (Dec21) was $6,501 Mil.
Long-Term Debt & Capital Lease Obligation was $48 Mil.
Total Current Assets was $2,693 Mil.
Total Current Liabilities was $678 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ono Pharmaceutical Co's current Net Income (TTM) was 892. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ono Pharmaceutical Co's current Cash Flow from Operations (TTM) was 751. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=891.8/6156.026
=0.14486618

ROA (Last Year)=Net Income/Total Assets (Dec21)
=830.417/6501.258
=0.12773174

Ono Pharmaceutical Co's return on assets of this year was 0.14486618. Ono Pharmaceutical Co's return on assets of last year was 0.12773174. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ono Pharmaceutical Co's current Net Income (TTM) was 892. Ono Pharmaceutical Co's current Cash Flow from Operations (TTM) was 751. ==> 751 <= 892 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=43.895/6235.7918
=0.0070392

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=47.852/6042.7958
=0.00791885

Ono Pharmaceutical Co's gearing of this year was 0.0070392. Ono Pharmaceutical Co's gearing of last year was 0.00791885. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=2460.538/623.052
=3.94916957

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=2693.114/678.473
=3.96937535

Ono Pharmaceutical Co's current ratio of this year was 3.94916957. Ono Pharmaceutical Co's current ratio of last year was 3.96937535. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ono Pharmaceutical Co's number of shares in issue this year was 1427.651. Ono Pharmaceutical Co's number of shares in issue last year was 1465.125. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2650.333/3507.555
=0.75560697

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2425.486/3229.272
=0.75109374

Ono Pharmaceutical Co's gross margin of this year was 0.75560697. Ono Pharmaceutical Co's gross margin of last year was 0.75109374. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=3507.555/6156.026
=0.56977586

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=3229.272/6501.258
=0.49671494

Ono Pharmaceutical Co's asset turnover of this year was 0.56977586. Ono Pharmaceutical Co's asset turnover of last year was 0.49671494. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ono Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Ono Pharmaceutical Co  (OTCPK:OPHLY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ono Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines